{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:56:36Z","timestamp":1772276196403,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adjuvant endocrine therapy is recommended for the treatment of hormone-receptor-positive breast cancer. Aromatase inhibitors are associated with significant musculoskeletal adverse effects, likely through growth hormone\/insulin-like growth factor 1 modulation, while tamoxifen reduces insulin-like growth factor 1 production. We describe the case of a patient who was treated successfully with tamoxifen for her hormone-receptor-positive breast cancer and acromegaly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 57-year old White female with hormone-receptor-positive breast cancer was diagnosed with acromegaly. She received adjuvant endocrine therapy with anastrozole but could not tolerate this medication because of severe arthralgia, so she was switched to tamoxifen. Shortly after starting tamoxifen, the patient\u2019s musculoskeletal symptoms resolved and her insulin-like growth factor 1 levels normalized. She has remained in remission of her acromegaly and breast cancer since initiating tamoxifen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly. Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer. We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. While tamoxifen may offer an additional, oral option for acromegaly patients who do not respond to or tolerate conventional growth-hormone-lowering therapy, additional studies are necessary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02792-8","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T23:04:57Z","timestamp":1619651097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-5737","authenticated-orcid":false,"given":"Sasan","family":"Mirfakhraee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Alberto V. Cabo","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloofar","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"4","key":"2792_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","volume":"26","author":"JD Nabarro","year":"1987","unstructured":"Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26(4):481\u2013512.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2792_CR2","first-page":"2730","volume":"83","author":"SM Orme","year":"1998","unstructured":"Orme SM, et\u00a0al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83(8):2730\u20134.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2792_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, et\u00a0al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423\u201338.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2792_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3816\/CBC.2007.n.038","volume":"7","author":"CA Presant","year":"2007","unstructured":"Presant CA, et\u00a0al. Aromatase inhibitor-associated arthralgia and\/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775\u20138.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"2792_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/annonc\/mdt037","volume":"24","author":"P Niravath","year":"2013","unstructured":"Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443\u20139.","journal-title":"Ann Oncol"},{"issue":"17","key":"2792_CR6","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1016\/j.ejca.2014.08.012","volume":"50","author":"A Lintermans","year":"2014","unstructured":"Lintermans A, et\u00a0al. Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. Eur J Cancer. 2014;50(17):2925\u201331.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2792_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1210\/jcem-72-2-374","volume":"72","author":"AJ Weissberger","year":"1991","unstructured":"Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72(2):374\u201381.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2792_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1073\/pnas.0337600100","volume":"100","author":"KC Leung","year":"2003","unstructured":"Leung KC, et\u00a0al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA. 2003;100(3):1016\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2792_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1056\/NEJMra022219","volume":"348","author":"BL Riggs","year":"2003","unstructured":"Riggs BL, Hartmann LC. Selective estrogen-receptor modulators\u2014mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"2792_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11102-013-0534-9","volume":"17","author":"I Balili","year":"2014","unstructured":"Balili I, Barkan A. Tamoxifen as a therapeutic agent in acromegaly. Pituitary. 2014;17(6):500\u20134.","journal-title":"Pituitary"},{"issue":"8","key":"2792_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF03348000","volume":"20","author":"R Cozzi","year":"1997","unstructured":"Cozzi R, et\u00a0al. Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest. 1997;20(8):445\u201351.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2792_CR12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1210\/jc.2014-3913","volume":"100","author":"FH Duarte","year":"2015","unstructured":"Duarte FH, Jallad RS, Bronstein MD. Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J Clin Endocrinol Metab. 2015;100(5):1863\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2792_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1210\/er.2008-0022","volume":"30","author":"DL Kleinberg","year":"2009","unstructured":"Kleinberg DL, et\u00a0al. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev. 2009;30(1):51\u201374.","journal-title":"Endocr Rev"},{"key":"2792_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2015.00059","volume":"6","author":"SM Farabaugh","year":"2015","unstructured":"Farabaugh SM, Boone DN, Lee AV. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol (Lausanne). 2015;6:59.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2792_CR15","doi-asserted-by":"crossref","unstructured":"Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530\u2013542.","DOI":"10.1016\/S1470-2045(10)70095-4"},{"issue":"6","key":"2792_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.breast.2013.07.038","volume":"22","author":"H Hartog","year":"2013","unstructured":"Hartog H, et\u00a0al. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast. 2013;22(6):1155\u201360.","journal-title":"Breast"},{"issue":"7","key":"2792_CR17","first-page":"1882","volume":"49","author":"RB Colletti","year":"1989","unstructured":"Colletti RB, et\u00a0al. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989;49(7):1882\u20134.","journal-title":"Cancer Res"},{"issue":"1","key":"2792_CR18","doi-asserted-by":"publisher","first-page":"T61","DOI":"10.1530\/JME-17-0261","volume":"61","author":"D Yee","year":"2018","unstructured":"Yee D. Anti-insulin-like growth factor therapy in breast cancer. J Mol Endocrinol. 2018;61(1):T61\u20138.","journal-title":"J Mol Endocrinol"},{"issue":"23","key":"2792_CR19","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1200\/JCO.2012.46.6383","volume":"31","author":"YK Chae","year":"2013","unstructured":"Chae YK, et\u00a0al. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013;31(23):e398-400.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2792_CR20","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1007\/s11102-010-0287-7","volume":"15","author":"JC Maiza","year":"2012","unstructured":"Maiza JC, et\u00a0al. Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. Pituitary. 2012;15(Suppl 1):S23\u20137.","journal-title":"Pituitary"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02792-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02792-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02792-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:08:54Z","timestamp":1619654934000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02792-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02792-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have stated explicitly that there are no conflicts of interest in connection with this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}